CA2287397A1 — Use of an nk-1 receptor antagonist and an ssri for treating obesity
Assigned to Organon Pharma UK Ltd · Expires 1998-10-29 · 28y expired
What this patent protects
The present invention provides the use of an NK-1 receptor antagonist and a selective serotonin reuptake inhibitor for the manufacture of a medicament for the treatment or prevention of obesity, methods of treatment using the NK-1 receptor antagonist and SSRI and pharmaceutical c…
USPTO Abstract
The present invention provides the use of an NK-1 receptor antagonist and a selective serotonin reuptake inhibitor for the manufacture of a medicament for the treatment or prevention of obesity, methods of treatment using the NK-1 receptor antagonist and SSRI and pharmaceutical compositions and products containing it.
Drugs covered by this patent
- Trulance (PLECANATIDE) · Salix
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.